Abstract
Objective: The aim of this study is to evaluate the effect of growth hormone therapy (rGH) on mitochondrial function on peripheral muscle and to correlate with exercise capacity in subjects with severe adult growth hormone deficiency (GHD). Design: Six months, double-blind, randomized, crossover, placebo-controlled trial of subcutaneous rGH in 17 patients with GHD. Measurements: Quadriceps muscle biopsies were obtained at baseline, 3 months, and 6 months to measure succinate dehydrogenase (SDH) to assess mitochondrial activity. Exercise capacity was measured with cardiopulmonary exercise testing. Lipids, glycemic parameters, and body fat levels were also measured. Results: Serum insulin-like growth factor 1 (IGF1) levels reduced fat mass by 3.2% (p < 0.05) and normalized with rGH in the active phase (p < 0.005). Patients showed an increase in SDH (p < 0.01) from base line that differed between placebo and rGH therapy treatment groups (p < 0.05): those treated by rGH followed by placebo showed a significant increase in SDH (p < 0.001) followed by a decrease, with a significant between group difference at the end of 6 months (p < 0.05). No significant improvements or correlation with exercise capacity was found. Conclusion: Short-term rGH for 3 months normalized IGF1 levels, reduced fat mass, and had a significant effect on mitochondrial function, but exercise capacity was unchanged.
| Original language | English |
|---|---|
| Article number | 56 |
| Journal | Frontiers in Endocrinology |
| Volume | 9 |
| Issue number | FEB |
| DOIs | |
| Publication status | Published - 23 Feb 2018 |
Fingerprint
Keywords
- Cardiovascular risk factors
- Exercise performance
- GH deficiency
- Mitochondrial dysfunction
- Succinate dehydrogenase
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
Cite this
Effects of growth hormone replacement on peripheral muscle and exercise capacity in severe growth hormone deficiency. / Gonzalez, Susana; Sathyapalan, Thozhukat; Javed, Zeeshan; Atkin, Stephen.
In: Frontiers in Endocrinology, Vol. 9, No. FEB, 56, 23.02.2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of growth hormone replacement on peripheral muscle and exercise capacity in severe growth hormone deficiency
AU - Gonzalez, Susana
AU - Sathyapalan, Thozhukat
AU - Javed, Zeeshan
AU - Atkin, Stephen
PY - 2018/2/23
Y1 - 2018/2/23
N2 - Objective: The aim of this study is to evaluate the effect of growth hormone therapy (rGH) on mitochondrial function on peripheral muscle and to correlate with exercise capacity in subjects with severe adult growth hormone deficiency (GHD). Design: Six months, double-blind, randomized, crossover, placebo-controlled trial of subcutaneous rGH in 17 patients with GHD. Measurements: Quadriceps muscle biopsies were obtained at baseline, 3 months, and 6 months to measure succinate dehydrogenase (SDH) to assess mitochondrial activity. Exercise capacity was measured with cardiopulmonary exercise testing. Lipids, glycemic parameters, and body fat levels were also measured. Results: Serum insulin-like growth factor 1 (IGF1) levels reduced fat mass by 3.2% (p < 0.05) and normalized with rGH in the active phase (p < 0.005). Patients showed an increase in SDH (p < 0.01) from base line that differed between placebo and rGH therapy treatment groups (p < 0.05): those treated by rGH followed by placebo showed a significant increase in SDH (p < 0.001) followed by a decrease, with a significant between group difference at the end of 6 months (p < 0.05). No significant improvements or correlation with exercise capacity was found. Conclusion: Short-term rGH for 3 months normalized IGF1 levels, reduced fat mass, and had a significant effect on mitochondrial function, but exercise capacity was unchanged.
AB - Objective: The aim of this study is to evaluate the effect of growth hormone therapy (rGH) on mitochondrial function on peripheral muscle and to correlate with exercise capacity in subjects with severe adult growth hormone deficiency (GHD). Design: Six months, double-blind, randomized, crossover, placebo-controlled trial of subcutaneous rGH in 17 patients with GHD. Measurements: Quadriceps muscle biopsies were obtained at baseline, 3 months, and 6 months to measure succinate dehydrogenase (SDH) to assess mitochondrial activity. Exercise capacity was measured with cardiopulmonary exercise testing. Lipids, glycemic parameters, and body fat levels were also measured. Results: Serum insulin-like growth factor 1 (IGF1) levels reduced fat mass by 3.2% (p < 0.05) and normalized with rGH in the active phase (p < 0.005). Patients showed an increase in SDH (p < 0.01) from base line that differed between placebo and rGH therapy treatment groups (p < 0.05): those treated by rGH followed by placebo showed a significant increase in SDH (p < 0.001) followed by a decrease, with a significant between group difference at the end of 6 months (p < 0.05). No significant improvements or correlation with exercise capacity was found. Conclusion: Short-term rGH for 3 months normalized IGF1 levels, reduced fat mass, and had a significant effect on mitochondrial function, but exercise capacity was unchanged.
KW - Cardiovascular risk factors
KW - Exercise performance
KW - GH deficiency
KW - Mitochondrial dysfunction
KW - Succinate dehydrogenase
UR - http://www.scopus.com/inward/record.url?scp=85042497846&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042497846&partnerID=8YFLogxK
U2 - 10.3389/fendo.2018.00056
DO - 10.3389/fendo.2018.00056
M3 - Article
VL - 9
JO - Frontiers in Endocrinology
JF - Frontiers in Endocrinology
SN - 1664-2392
IS - FEB
M1 - 56
ER -